Cargando…
COVID-19: Abnormal liver function tests
BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnorm...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194951/ https://www.ncbi.nlm.nih.gov/pubmed/32298767 http://dx.doi.org/10.1016/j.jhep.2020.04.006 |
_version_ | 1783528438158589952 |
---|---|
author | Cai, Qingxian Huang, Deliang Yu, Hong Zhu, Zhibin Xia, Zhang Su, Yinan Li, Zhiwei Zhou, Guangde Gou, Jizhou Qu, Jiuxin Sun, Yan Liu, Yingxia He, Qing Chen, Jun Liu, Lei Xu, Lin |
author_facet | Cai, Qingxian Huang, Deliang Yu, Hong Zhu, Zhibin Xia, Zhang Su, Yinan Li, Zhiwei Zhou, Guangde Gou, Jizhou Qu, Jiuxin Sun, Yan Liu, Yingxia He, Qing Chen, Jun Liu, Lei Xu, Lin |
author_sort | Cai, Qingxian |
collection | PubMed |
description | BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients. |
format | Online Article Text |
id | pubmed-7194951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Association for the Study of the Liver. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71949512020-05-02 COVID-19: Abnormal liver function tests Cai, Qingxian Huang, Deliang Yu, Hong Zhu, Zhibin Xia, Zhang Su, Yinan Li, Zhiwei Zhou, Guangde Gou, Jizhou Qu, Jiuxin Sun, Yan Liu, Yingxia He, Qing Chen, Jun Liu, Lei Xu, Lin J Hepatol Research Article BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients. European Association for the Study of the Liver. Published by Elsevier B.V. 2020-09 2020-04-13 /pmc/articles/PMC7194951/ /pubmed/32298767 http://dx.doi.org/10.1016/j.jhep.2020.04.006 Text en © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Research Article Cai, Qingxian Huang, Deliang Yu, Hong Zhu, Zhibin Xia, Zhang Su, Yinan Li, Zhiwei Zhou, Guangde Gou, Jizhou Qu, Jiuxin Sun, Yan Liu, Yingxia He, Qing Chen, Jun Liu, Lei Xu, Lin COVID-19: Abnormal liver function tests |
title | COVID-19: Abnormal liver function tests |
title_full | COVID-19: Abnormal liver function tests |
title_fullStr | COVID-19: Abnormal liver function tests |
title_full_unstemmed | COVID-19: Abnormal liver function tests |
title_short | COVID-19: Abnormal liver function tests |
title_sort | covid-19: abnormal liver function tests |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194951/ https://www.ncbi.nlm.nih.gov/pubmed/32298767 http://dx.doi.org/10.1016/j.jhep.2020.04.006 |
work_keys_str_mv | AT caiqingxian covid19abnormalliverfunctiontests AT huangdeliang covid19abnormalliverfunctiontests AT yuhong covid19abnormalliverfunctiontests AT zhuzhibin covid19abnormalliverfunctiontests AT xiazhang covid19abnormalliverfunctiontests AT suyinan covid19abnormalliverfunctiontests AT lizhiwei covid19abnormalliverfunctiontests AT zhouguangde covid19abnormalliverfunctiontests AT goujizhou covid19abnormalliverfunctiontests AT qujiuxin covid19abnormalliverfunctiontests AT sunyan covid19abnormalliverfunctiontests AT liuyingxia covid19abnormalliverfunctiontests AT heqing covid19abnormalliverfunctiontests AT chenjun covid19abnormalliverfunctiontests AT liulei covid19abnormalliverfunctiontests AT xulin covid19abnormalliverfunctiontests |